Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$43.50 USD
+0.70 (1.64%)
Updated May 14, 2024 04:00 PM ET
After-Market: $43.50 0.00 (0.00%) 7:10 PM ET
4-Sell of 5 4
D Value D Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Soleno Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 170 | 15 | 21 | 49 | 21 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 1 | 1 | 0 |
Total Current Assets | 171 | 16 | 22 | 50 | 21 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 9 | 11 | 13 | 15 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 181 | 27 | 36 | 65 | 38 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 5 | 4 | 5 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 7 | 8 | 9 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12 | 9 | 10 | 11 | 18 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 16 | 18 | 19 | 23 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 434 | 248 | 231 | 228 | 173 |
Retained Earnings | -276 | -237 | -213 | -182 | -158 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 158 | 10 | 18 | 46 | 15 |
Total Liabilities & Shareholder's Equity | 181 | 27 | 36 | 65 | 38 |
Total Common Equity | 158 | 10 | 18 | 46 | 15 |
Shares Outstanding | 30.50 | 8.10 | 5.30 | 5.30 | 2.90 |
Book Value Per Share | 5.16 | 1.28 | 3.36 | 8.59 | 5.16 |
Fiscal Year End for Soleno Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 150 | 170 | 52 | 19 | 8 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 1 | 1 | 1 |
Total Current Assets | 151 | 171 | 54 | 21 | 9 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 9 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 8 | 9 | 9 | 10 | 10 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 169 | 181 | 64 | 31 | 20 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 3 | 3 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 7 | 5 | 5 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 21 | 1 | 1 |
Total Current Liabilities | 13 | 12 | 29 | 9 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12 | 11 | 9 | 9 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 23 | 40 | 19 | 17 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 441 | 434 | 288 | 267 | 248 |
Retained Earnings | -298 | -276 | -265 | -254 | -246 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 143 | 158 | 23 | 12 | 3 |
Total Liabilities & Shareholder's Equity | 169 | 181 | 64 | 31 | 20 |
Total Common Equity | 143 | 158 | 23 | 12 | 3 |
Shares Outstanding | 33.40 | 30.50 | 15.40 | 8.10 | 8.10 |
Book Value Per Share | 4.29 | 5.16 | 1.51 | 1.53 | 0.33 |